Cytomx Therapeutics (CTMX) Stock
Clinical stage biotech developing targeted cancer antibody treatments. Here's the price, business snapshot, and what's worth knowing about Cytomx Therapeutics in July 2026.
CytomX Therapeutics (CTMX) is a clinical‑stage biotechnology company developing conditionally activated antibody therapeutics using its Probody platform. The approach is designed to keep antibody drugs inactive in circulation and activate them within the tumour microenvironment, with the goal of widening the therapeutic window and lowering off‑tumour toxicity. Investors should be aware this is an early‑stage company: value is driven by clinical readouts, regulatory progress and potential partnerships or licensing deals rather than steady revenues. As a small‑cap stock, CytomX can be more volatile and may require additional financing to advance programmes. Key considerations for investors include trial results, cash runway, management execution and the broader oncology funding environment. This summary is for educational purposes only and not personalised investment advice; any investment could lose value and past performance is not a reliable indicator of future results.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying CytomX Therapeutics' stock with a target price of $7.07, indicating growth potential.
Financial Health
CytomX Therapeutics is maintaining steady revenue and cash flow, but faces challenges in profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring CTMX
Precision Oncology Stocks: Could This Theme Gain Momentum?
Revolution Medicines recently reported stellar Phase 3 trial results for its pancreatic cancer drug, sending its stock soaring and validating novel targeted therapies. This breakthrough creates a compelling investment opportunity across the broader oncology sector, particularly for biotechnology firms specializing in genetic mutations and precision medicine.
Published: 14 April 2026
Explore BasketPrecision Oncology RAS Inhibitor Stocks to Watch 2026
Former Senator Ben Sasse recently spotlighted Revolution Medicines' upcoming Phase 3 trial results for a new pancreatic cancer pill. This high-profile endorsement brings broader market attention to biotech companies developing innovative therapies for historically untreatable, RAS-dependent solid tumors.
Published: 12 April 2026
Explore BasketPharma Stocks: Could Pipeline Power Drive Growth?
Pharmaceutical giant Roche boosted its earnings outlook, fueled by strong sales of its innovative cancer, immunology, and diagnostic products. This success highlights a broader investment opportunity in leading drugmakers with powerful research and development engines poised for growth.
Published: 23 October 2025
Explore BasketOncology Stocks: Partnership Boom or Bubble Risk?
China's Innovent Biologics and Japan's Takeda Pharmaceutical have signed a multi-billion dollar deal to co-develop advanced cancer therapies. This landmark partnership signals a growing trend of international collaborations, creating potential investment opportunities among other biotech firms specializing in immuno-oncology and antibody-drug conjugates.
Published: 22 October 2025
Explore BasketOncology Stocks: Could Combination Therapies Drive Growth?
Astellas and Pfizer's successful trial for a new combination bladder cancer therapy highlights a significant advancement in oncology. This breakthrough signals a promising investment opportunity in the broader field of innovative cancer treatments, especially among companies developing combination therapies and targeted drugs.
Published: 19 October 2025
Explore BasketFDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: 12 October 2025
Explore BasketCancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: 11 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Probody Activation Platform
Aims to activate antibodies at the tumour site to reduce off‑tumour effects; scientific promise carries clinical and regulatory risk, so outcomes can vary.
Event‑Driven Catalysts
Share moves often follow trial readouts, licensing deals or financing updates; these can create rapid gains or losses depending on outcomes.
Partnering & Licensing
Biotech partnerships can accelerate development and de‑risk programmes, though they depend on negotiation and regulatory progress.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
